Physician profile
Lori E Fox
NPI 1033551270
$4,409.61
in general payments reported to CMS, 2019-2025
22 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $593 · 2022: $200 · 2023: $718 · 2024: $1,233 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,616.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $751.24 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $729.06 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $599.47 | 2022-2025 | Caplyta |
| Lundbeck LLC | $390.70 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $333.11 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $321.13 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $176.65 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $176.62 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $172.34 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Bausch Health US, LLC | $167.88 | 2023-2025 | Aplenzin |
| Axsome Therapeutics, INC. | $137.51 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $123.44 | 2024-2025 | Spravato |
| Corium, LLC | $88.78 | 2023-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $74.04 | 2024 | |
| Noven Therapeutics, LLC | $47.13 | 2023-2024 | Xelstrym, Secuado |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $21.79 | 2025 | Quviviq |
| Sunovion Pharmaceuticals INC. | $21.74 | 2021 | |
| Collegium Pharmaceutical, INC. | $18.78 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $18.04 | 2023 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $17.56 | 2024 | Cobenfy |
| Acadia Pharmaceuticals INC | $15.48 | 2025 | Nuplazid |
| Tms Neurohealth Centers INC. | $7.12 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.